Sinovac Biotech, Receivables

Sinovac Biotech, (SVA) currently reports a receivables of $400M as of June 2024. That compares with $500M in the prior-year period — down 19.1% year over year. Use the charts on this page to explore Sinovac Biotech,'s receivables history and peer comparisons.

Sinovac Biotech,'s receivables decreased from $500M to $400M — a 19.1% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sinovac Biotech, reported $400M in receivables as of June 2024. That compares with $500M in the prior-year period — down 19.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $400M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.

Sinovac Biotech, is classified in the Healthcare sector. On receivables, it currently shows $400M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SVA with unrelated industries.